Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

This study is testing a combination of two cancer drugs — CPX-351 (a type of chemotherapy) and quizartinib — for people with a specific type of blood cancer called acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), particularly those with a FLT3 gene mutation. **You may be eligible if...** - You have been diagnosed with AML or high-risk MDS - If newly diagnosed: you are 60 or older and have not had prior chemotherapy for this cancer - If relapsed or returned: you are 18 or older and have received at least one prior treatment - Your heart, liver, and kidney function are within acceptable levels - You are able to swallow oral medications **You may NOT be eligible if...** - You have a known allergy to quizartinib or CPX-351 - You have serious heart problems (abnormal heart rhythm, heart failure, recent heart attack) - You have a congenital long QT syndrome (a heart electrical condition) - You have HIV, active hepatitis B or C - You have recently eaten grapefruit or Seville oranges (within 3 days) - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.